insights

Deal Terms Analysis

Expert insights into M&A deal terms and key trends.

Filter

Format

Deal Terms Analysis

Valuation Disconnects Driving a Spike in Earnouts in M&A

Deal Terms Analysis

Lower Middle-Market Mergers & Acquisitions Deals Report

Deal Terms Analysis

Life Sciences

2023 SRS Acquiom Life Sciences M&A Study

Deal Terms Analysis

2023 M&A Deal Terms and Trends for Private Equity Buyers

Deal Terms Analysis

Technology M&A Deal Terms and Trends

Deal Terms Analysis

Escrow and Payments

Effect of Representations and Warranties Insurance on Deal Terms

Deal Terms Analysis

Private M&A Deal Terms: An SRS Acquiom Quick Guide for M&A Advisors

Deal Terms Analysis

Tools and Tactics for Getting Deals Across the Finish Line

Deal Terms Analysis

Tools for Practitioners

Deal Terms for M&A Escrows - Statistics and Key Findings

Deal Terms Analysis

2023 M&A Deal Terms Study

Deal Terms Analysis

M&A Trends: PPAs and Claims Activity

Deal Terms Analysis

Post-Closing M&A Claims and Purchase Price Adjustments: Where Do They Stand Heading Into 2023?

Deal Terms Analysis

2022 PE-Buyer Deal Terms

Deal Terms Analysis

Tools for Practitioners

How M&A Advisors Use Deal Data to Improve the Due Diligence Process

Deal Terms Analysis

2022 M&A Deal Terms Study Update with Key Findings

Deal Terms Analysis

Tools for Practitioners

2022 M&A Claims Insights Report

Deal Terms Analysis

2022 Technology M&A Deals Special Report

Deal Terms Analysis

Tools for Practitioners

2022 M&A Deal Terms Study

Deal Terms Analysis

Life Sciences

Tools for Practitioners

2021 Life Sciences M&A Study

Deal Terms Analysis

Tools for Practitioners

2021 M&A Deal Terms Study Key Findings

Deal Terms Analysis

Tools for Practitioners

2021 M&A Deal Terms Study

Deal Terms Analysis

2020 M&A Claims Insights Report

Deal Terms Analysis

Shareholder Representation

What to Make of the Great Hill Case – The M&A Bar is Not Yet in Agreement on How Best to Address Merger Agreement Privilege Issues

Deal Terms Analysis

2020 Review: COVID-19 Impact on M&A Transactions

Deal Terms Analysis

M&A Deal Terms & Trends Pre- & Post-COVID-19

Deal Terms Analysis

Shareholder Representation

M&A: Who Owns the Attorney-Client Privilege After Closing?

Deal Terms Analysis

Tools for Practitioners

Escrow and Payments

2020 Buy-Side Reps and Warranties Insurance Deal Terms Update

Deal Terms Analysis

A First Look at the Impacts of Coronavirus on M&A Transactions

Deal Terms Analysis

Tools for Practitioners

Buyer Power Ratio

Deal Terms Analysis

Life Sciences

Life Sciences: Milestone Trends by Product Stage

Deal Terms Analysis

Life Sciences

Life Sciences: Timeline of Milestone Payments

Deal Terms Analysis

Shareholder Representation

Addressing Target Company Privilege in Merger Agreements Five Years after Great Hill v. SIG

Deal Terms Analysis

Shareholder Representation

Beware of Exclusions When Defining Net Working Capital in M&A Transactions

Deal Terms Analysis

Life Sciences

Tools for Practitioners

2019 Life Sciences Study Quick Reference Guide

Deal Terms Analysis

Life Sciences

Tools for Practitioners

2019 Life Sciences M&A Study

Deal Terms Analysis

Escrow and Payments

Allocation and Assignment of Interest

Deal Terms Analysis

Shareholder Representation

Tools for Practitioners

M&A Privilege: What to Make of the Great Hill Case— Who Owns the Attorney-Client Privilege After Closing and How Can it Really be Addressed?

Deal Terms Analysis

2018 M&A Claims Insights Report

Deal Terms Analysis

Shareholder Representation

Understanding Changes in Shareholder Consent Requirements

Deal Terms Analysis

Tools for Practitioners

Impact of “Buyer Power Ratio” on M&A Deal Terms

Deal Terms Analysis

Shareholder Representation

Definition of Purchase Price

Deal Terms Analysis

Shareholder Representation

Do Carveouts to Caps Work the Way You Intend?

Deal Terms Analysis

Shareholder Representation

M&A Conflict Waivers

Deal Terms Analysis

Shareholder Representation

Clarifying When Attorneys’ Fees Constitute Damages